National Meeting Highlights from PAINWeek 2012
Release Date: October 08, 2012
Expiration Date: October 08, 2013
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
This educational initiative offers highlights from seven key sessions held at PAINWeek 2012. Experts on pain management, addiction medicine law enforcement and regulatory issues will offer clinical perspectives on the challenges of managing chronic pain.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in pain management.
Upon completion of this educational activity, participants should be able to:
- Identify and evaluate therapeutic implications of new conference data from PAINWeek’s 2012 meeting related to pain management
Rational Opioid Prescribing – Charles Argoff, MD
Legal and Regulatory Dangers and Disconnects in Pain Management − Jennifer Bolen, JD
State Prescription Monitoring Programs – Aaron Gilson, PhD, MSSW
Opioids from A to Z –Thomas Gregory, PharmD
New Opioid Delivery Systems and Urine Drug Monitoring for Patients on Long-term Opioid Therapy – Jeffrey A. Gudin, MD
Chronic Disease Management in a Primary Care Office Surrounding Pain Management – Christopher Herndon, PharmD
Intellectual Honesty and Dishonesty and Arguments Made Around Opioid Therapy – Steven D. Passik, PhD
Instructions for Participation and Credit
This activity is eligible for credit through October 8, 2013. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Charles E. Argoff, MD
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, New York
Dr. Charles Argoff received his medical degree from Northwestern University’s Feinberg School of Medicine in Chicago, Illinois. He completed an internship in the Department of Medicine, a residency in the Department of Neurology at the State University of New York in Stony Brook, and a fellowship in developmental and metabolic neurology at the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS). He is currently a professor of neurology at Albany Medical College and director of the Comprehensive Pain Center at Albany Medical Center in New York.
Dr. Argoff is a member of the International Association for the Study of Pain, the American Academy of Pain Medicine, and the American Academy of Neurology, among others. He serves on the editorial board of the Clinical Journal of Pain, and as a reviewer for the Journal of Pain, Brain, JAMA, Archives of Physical Medicine and Rehabilitation, Journal of Musculoskeletal Pain, Journal of Pain and Symptom Management, and the Clinical Journal of Pain. He is co-editor of the neuropathic pain section of Pain Medicine and is one of the editors of the recently published textbook Raj’s Practical Management of Pain. In addition, Dr. Argoff has served as a guest editor for and published articles in the Clinical Journal of Pain, and Current Pain and Headache Reports, among others. He has written on many types of pain, including myofascial pain, neuropathic pain, spinal and radicular pain, and on such treatments as topical analgesics, interventional pain management, botulinum toxins, and oral analgesics. Dr. Argoff had an active role in the development of the diabetic peripheral neuropathic pain guidelines published in MayoClinic Proceedings, and he has contributed to other published neuropathic pain treatment guidelines.
Jennifer Bolen, JD
Founder, The Legal Side of Pain and The Pain Lawyer™
A Division of the J. Bolen Group, LLC
Ms. Jennifer Bolen owns and operates The Legal Side of Pain®, a medico-legal consulting firm specializing in the development and implementation of regulatory compliance programs and patient risk management protocols for the use of controlled substances to treat pain and the office-based treatment of opioid addiction. She conducts compliance audits, chart reviews, practice evaluations, and designs compliance materials for her clients nationwide. Ms. Bolen also serves as an expert legal consultant to defense counsel involved in administrative, civil, and criminal litigation. She reviews medical charts, helps legal counsel select medical experts, and assembles a litigation strategy to challenge opposing experts. She testifies on behalf of physicians concerning pain policy and regulations, and is qualified in court as a nationally recognized expert in this area. Ms. Bolen is responsible for the development of the Prescriber’s PROOF™ System, which is a documentation toolkit designed to help clinicians meet federal and state regulatory requirements for controlled substance prescribing.
In January 2006, the American Academy of Pain Medicine appointed Ms. Bolen to serve as Special Counsel to Academy Members. She is the legal editor for Pain Medicine News, she serves on the editorial board for and publishes in Pain Medicine, and she also publishes in The Journal of Opioid Management and Practical Pain Management. Ms. Bolen serves as guest faculty with the University of Florida’s College of Pharmacy, and co-teaches a course on Federal Regulation of Controlled Substances.
Aaron M. Gilson, PhD, MSSW
Director, US Program
Pain & Policy Studies Group/WHO Collaborating Center
Carbone Comprehensive Cancer Center
University of Wisconsin-Madison
Dr. Aaron Gilson received a PhD in social welfare and an MS degree in social work from the University of Wisconsin in Madison where he had a dual concentration in social policy and in child maltreatment, with emphasis on prevention, theory, and survey research. He also received an MS degree in psychology from Villanova University in Pennsylvania. Dr. Gilson is director of the US Program at the Pain & Policy Studies Group (PPSG)/WHO Collaborating Center for Policy and Communications in Cancer Care, a division of the Paul P. Carbone Comprehensive Cancer Center at the University of Wisconsin School of Medicine and Public Health.
A member of the American Pain Society, the Liaison Committee on Pain and Addiction, the American Academy of Pain Medicine, and the American Society of Addiction Medicine, Dr. Gilson has published and presented about topics relevant to health care professionals and regulators both in the United States and abroad. His recent activities involve developing a methodology to evaluate and quantify federal and state controlled substances and health care practice policies. Dr. Gilson currently is examining the extent that prescription opioid analgesics are being diverted by pharmacy thefts, and working to promote a public health approach to prescription medication abuse by identifying the sources of diversion.
Thomas Gregory, PharmD
Clinical Lead Pharmacist
Trauma and Orthopedic Surgery Services
Truman Medical Centers
Kansas City, Missouri
Dr. Thomas Gregory received his doctor of pharmacy degree from the University of Missouri – Kansas City School of Pharmacy. He completed his general pharmacy practice residency in Cooperstown, New York. Dr. Gregory currently serves as the clinical lead pharmacist for the trauma and orthopedic surgery services for Truman Medical Centers in Kansas City, Missouri. He also serves as a clinical assistant professor to the University of Missouri – Kansas City School of Pharmacy, and adjunct faculty in pharmacy practice for the St. Louis College of Pharmacy, Ohio Northern University Raabe College of Pharmacy and Roseman University of Health Sciences – College of Pharmacy.
Dr. Gregory is a board certified pharmacotherapy specialist and certified pain educator, and serves on the clinical advisory board for the American Society of Pain Educators (ASPE) and is a distinguished member of ASPE. He also works within the multidisciplinary sickle cell clinic and serves as the one of the corporate pain committee co-chairs for Truman Medical Centers.
Jeffrey A. Gudin, MD
Pain Management Center
Englewood Hospital and Medical Center
Englewood, New Jersey
Dr. Jeffrey A. Gudin received his medical degree from Albany Medical College in Albany, New York. Following a transitional internship in surgery, medicine, and anesthesiology at St. Barnabas Medical Center in Livingston, New Jersey, he completed a residency in anesthesiology at Yale University School of Medicine. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching. He is currently director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey, an affiliate of the Mount Sinai School of Medicine. Dr. Gudin is board certified in pain medicine and anesthesiology, and is board eligible in addiction medicine.
An active speaker in the field of pain management, Dr. Gudin has been interviewed on various television news channels, including CBS, and other national news networks. Dr. Gudin has also been quoted in The New York Times and various regional newspapers in New Jersey and Connecticut. His clinical and research focus includes pain management, regional anesthesia, and preemptive analgesia, as well as increasing clinician awareness of pain assessment and management.
Chris Herndon, PharmD
Southern Illinois University Edwardsville
Clinical Pharmacy Specialist
St. Elizabeth’s Hospital
Dr. Chris Herndon received his doctor of pharmacy degree from the St. Louis College of Pharmacy. He then completed a geriatric pharmacotherapy specialty residency at the University of New Mexico Health Sciences Center. He is an assistant professor at Southern Illinois University Edwardsville, and a clinical pharmacy specialist at St. Elizabeth’s Hospital in Belleville, Illinois.
Dr. Herndon is a certified pain educator, American Society of Pain Educators, and a pharmacotherapy specialist, Board of Pharmaceutical Specialties, and is also a member of the International Association for the Study of Pain, American Society of Pain Educators, American Pain Society, and a fellow, American Society of Health-System Pharmacists. He holds editorial board positions at Journal of Pain and Palliative Care Pharmacotherapy and Journal of Opioid Management, and is an ad hoc reviewer for several professional publications. He has lectured and published numerous manuscripts, book chapters and abstracts and his research interests focus on pain and palliative care.
Steven D. Passik, PhD
Professor of Psychiatry and Anesthesiology
Vanderbilt University Medical Center
Dr. Steven Passik received his doctorate in clinical psychology from the New School for Social Research in New York City, and was chief fellow in the psychiatry service at Memorial Sloan-Kettering Cancer Center. Currently he is professor of psychiatry and anesthesiology at Vanderbilt University Medical Center in Nashville, Tennessee.
In 1999, Dr. Passik was a faculty scholar for the SOROS Foundation’s Project on Death in America. He has served on the editorial board of the Journal of Pain and Symptom Management, and has been a reviewer for the Journal of Pharmaceutical Care in Pain and Symptom Control, Journal of Pain and Symptom Management, Psycho-Oncology, Agency for Health Care Policy and Research Cancer Pain Guidelines, Cancer Investigation, and Oncology. Dr. Passik has served as the president of the Indiana Cancer and AIDS Pain Initiative and as editor in chief of the National Cancer Institute’s PDQ Supportive Care Editorial Board. He is the author of more than 120 journal articles, 60 book chapters, and 59 abstracts.
Dr. Passik was recently named a Fellow of DIV 28 of APA (Psychopharmacology & Substance Abuse), awarded a MayDay Fund Pain & Society Fellowship, given the academy of psychosomatic medicine Visiting Professor Award, and the American Psycho-Oncology Excellence in Clinical Care Award where he also serves on the advisory board. In addition, he received the Elizabeth Narcessian Award for Outstanding Educational Achievements. He speaks nationally and internationally on pain, addiction and the pain/addiction interface.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-12-327-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 12-327-292
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Charles Argoff has received honoraria related to speaker’s bureau and formal advisory activities from Eli Lilly and Company, Endo Pharmaceuticals Inc., Forest Pharmaceuticals, Inc. (a subsidiary of Forest Laboratories, Inc.), Pfizer Inc., and PriCara®, Division of Janssen Pharmaceuticals, Inc., as well as formal advisory activities from Bristol-Myers Squibb, Jazz Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, and Abbott Laboratories. He has received grant support related to research activities from Eli Lilly, Endo, Forest, and Pfizer.
Jennifer Bolen has received consultant fees from Abbott Laboratories, Avee Laboratories, Inc., Capital Toxicology, LLC, Teva Pharmaceuticals, Pfizer Inc., Meda Pharmaceuticals Inc., and Millennium Pharmaceuticals, Inc., as well as honoraria related to speakers’ bureau activities from Calloway Labs, Capital Toxicology, Teva, and PriCara®, Division of Janssen Pharmaceuticals, Inc. She owns significant holdings in Abbott and Pfizer.
Dr. Aaron Gilson and Dr. Christopher Herndon have disclosed no relevant financial relationships.
Dr. Thomas Gregory has received honoraria related to speakers’ bureau activities from Aventine HealthSciences.
Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from Pfizer Inc., Purdue Pharma L.P., and Teva Pharmaceuticals.
Dr. Steven Passik has received honoraria related to speakers’ bureau activities from Ameritox, Ltd.; Teva Pharmaceuticals; Covidien; Endo Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc. (A wholly-owned subsidiary of Takeda Pharmaceutical Company Limited); Purdue Pharma L.P.; Signature Therapeutics; Pfizer Inc.; and Quest Pharmaceuticals, Inc. He has received grant support related to research activities from Covidien.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Bronwyn Boyes, PharmD, director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Argoff has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Argoff has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Drs. Gilson, Gregory, Gudin, Herndon, Passik, and Ms. Bolen have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Gilson, Gregory, Gudin, Herndon, Passik, and Ms. Bolen have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Salix Pharmaceuticals, Inc.
©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.